Dr. Reddy's Laboratories Announces the Launch of Ertapenem for Injection in the U.S. Market
May 12 2021 - 12:56AM
Business Wire
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:
RDY, NSEIFSC: DRREDDY, along with its subsidiaries together
referred to as “Dr. Reddy’s”) today announced the launch of
Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic
version of INVANZ (ertapenem for injection) for injection, 1 g/vial
approved by the U.S. Food and Drug Administration (USFDA).
“We are pleased to bring this important product to market at
this time,” says Marc Kikuchi, CEO, North America Generics, Dr.
Reddy’s Laboratories. “We’re excited to extend our strategic
partnership with Gland Pharma whose hard work, in collaboration
with the team at Dr. Reddy’s, has enabled the execution of this
launch.”
"We are delighted about this collaboration, as it brings
together Dr. Reddy’s experienced marketing and distribution
capabilities and Gland Pharma’s robust development and
manufacturing capabilities. Gland Pharma has an exclusive API
supply arrangement for this product and a dedicated manufacturing
facility in Hyderabad for Ertapenem Injection. With the launch of
this product we see increased capacity utilization of this
dedicated Penem facility,” says Mr. Srinivas Sadu, MD and CEO of
Gland Pharma Ltd.
The INVANZ brand and generic market had U.S. sales of
approximately $205 million MAT for the most recent twelve months
ending in March 2021 according to IQVIA Health*.
Dr. Reddy’s Ertapenem for Injection, 1 g/vial, is available in
packs of 10 vials per carton.
Please click here for full prescribing information:
https://www.drreddys.com/media/986993/100962_ertapenem_for_injection_leaflet-original.pdf
INVANZ is a trademark of Merck and Co., Inc
*IQVIA Retail and Non-Retail MAT March 2021
RDY-0421-338
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines
for healthier lives. Through its three businesses – Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products – Dr. Reddy’s offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr. Reddy’s operates in
markets across the globe. Our major markets include – USA, India,
Russia & CIS countries, and Europe. For more information, log
on to: www.drreddys.com
About Gland Pharma Limited (BSE: 543245, NSE: GLAND): Gland
Pharma was established in 1978 in Hyderabad, has grown over the
years from a contract manufacturer of small volume liquid
parenteral products, to become one of the largest and fastest
growing injectable-focused companies, with a global footprint
across 60 countries, including the United States, Europe, Canada,
Australia, India and other markets. It operates primarily under a
business to business (B2B) model and have an excellent track record
in the development, manufacturing and marketing of complex
injectables. It has a wide range of injectables, including vials,
ampoules, pre-filled syringes, lyophilized vials, dry powders,
infusions, oncology and ophthalmic solutions and also enjoys the
distinction of having pioneered Heparin technology in India. For
more information, log on to: www.glandpharma.com
Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on
the management’s current views and assumptions and involve known or
unknown risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. In addition to statements which are
forward-looking by reason of context, the words "may", "will",
"should", "expects", "plans", "intends", "anticipates", "believes",
"estimates", "predicts", "potential", or "continue" and similar
expressions identify forward-looking statements. Actual results,
performance or events may differ materially from those in such
statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults , currency exchange rates, interest rates, persistency
levels and frequency / severity of insured loss events, (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization,
including related integration issues, and (vi) the susceptibility
of our industry and the markets addressed by our, and our
customers’, products and services to economic downturns as a result
of natural disasters, epidemics, pandemics or other widespread
illness, including coronavirus (or COVID-19), and (vii) other risks
and uncertainties identified in our public filings with the
Securities and Exchange Commission, including those listed under
the "Risk Factors" and "Forward-Looking Statements" sections of our
Annual Report on Form 20-F for the year ended March 31, 2020. The
company assumes no obligation to update any information contained
herein.”
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210511006310/en/
INVESTOR RELATIONS AMIT AGARWAL amita@drreddys.com (PH: +91-98661 74248) MEDIA
RELATIONS USHA IYER ushaiyer@drreddys.com (PH: +91-99874 44106)
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Sep 2023 to Sep 2024